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The necessity for a deeper understanding of neurological
diseases such as Alzheimer’s disease (AD) that increase in
frequency as a function of age has become of paramount
importance with the coming of age of the baby boom generation and the increasing social demands for individuals to
perform better and longer. AD is characterized by a gradual
decline in cognitive function and presence of pathological
inclusions such as Aβ plaques and neurofibrillary tangles
composed of hyper-phosphorylated tau in the brain. These
are the main hallmarks of the disease and focus of most
current therapeutic strategies. As such, the development of
transgenic and non-transgenic models of AD over the last
decade has primarily focused on these pathological markers.
These models have become promising tools to decipher
the mechanistic importance of tau phosphorylation and Aβ
deposits, as well the relationship between each other, other
pathological AD-related events, and cognitive loss. However,
while seemingly obvious, it is important to remember that
the validity of an animal model of disease is tightly linked to
the ability of the animal to mimic the signs of the disease—
which goes beyond the pathology and needs to include
cognitive decline and neuronal loss. This special issue seeks
to provide an updated and critical evaluation of the available
animal models of AD with the primary goal to deepen our
mechanistic understanding of AD and elucidate how the
development of these models has led or can lead to novel
therapies for AD patients.
The topics included in this special issue are the following:
(i) Development of novel transgenic or non-transgenic
animal models of AD (rodents or other).

(ii) Mechanistic studies of AD-related pathology in animal models including but not limited to APP/Aβ and/
or tau hyper-phosphorylation (i.e., oxidative stress,
mitochondrial, inflammatory, cell cycle changes etc.)
(iii) Development of novel behavioral or translational
methodologies to determine impairment in models
of AD.
(iv) Novel therapeutic approaches to modulate AD
pathology and cognitive impairment.
In the coming years, prevalence of Alzheimer’s disease
(AD) is said to overtake diseases such as AIDS or cardiovascular diseases (World Health Organization). The impact
of this disease on millions of individuals, their families,
and the health care system will be devastating. As such, the
scientific community has strived to model AD in the hope
that these models will provide the tools for eﬀective and
desperately needed therapeutic development and testing. At
the forefront of the quest to decipher Alzheimer’s disease
are animal models. Developed through genetic, chemical,
and/or lesions, animal models of AD try to faithfully mimic
disease pathogenesis in a growing number of species ranging
from invertebrates to higher mammals such as primates. The
ultimate goal is to further our understanding of mechanisms
associated with this plural and complex disease and allow us
to test promising therapies to manage, prevent, and hopefully
cure AD.
Novel animal models of AD are relentlessly being developed and existing ones fine-tuned; however, they face the
challenges associated with the complexity of a neurodegenerative disease. For example, most animal models of AD do not
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reproduce the full phenotypical disease spectrum. Also relevant is the fact that, like for most neurodegenerative diseases,
the etiology of AD and the clinical presentation diﬀers greatly
across individuals. As such, while the current models are very
well suited for the study of specific pathology-driven mechanisms, most notably amyloid-beta, pharmacological testing
in animal models of neurodegenerative disease often translates into poor eﬃcacy when applied to the clinical population. With these advances and challenges in mind, this special
issue, written by experts in the field, provides a rich and
updated overview of disease-related aspects modeled in several species, ranging from the established transgenic models
but also including novel drosophila and chick models. A wide
range of modeled disease-related events are discussed at all
levels, from descriptive and mechanistic to technical in order
to provide a full scope of this disease and additional techniques that may become useful to investigators in the field.
An important aim of this special issue is to provide an
accurate picture of the plurality of this disease by presenting
research that is not only focused on modeling primary
pathology. This includes, the downstream impact of tau
phosphorylation in both murine and drosophila models
and presenilin-mediated signaling, and also disease-related
events that go beyond classical pathology. This special issue
includes primary research and review articles on oxidative
stress and mitochondrial dysfunction, lipid raft alterations
in the murine models of the disease, and attention to various
enzymatic complexes including the 2-oxoglutarate dehydrogenase complex. Furthermore, classic neurotransmitter
systems such as acetylcholine, and brain regions such as the
locus coeruleus are also discussed in an attempt to highlight
the importance of these alternate or additional processes
in the disease and provide a breath of how AD can be
modeled at diﬀerent levels. In conjunction with these articles,
this issue also includes in depth discussion of biomarkers,
imaging, and behavioral techniques, and studies presenting
gender diﬀerences in murine and nonmurine models of AD
that provide additional insight to investigators in the field.
Taken together, the ultimate outcome of this exciting
and plural special issue is to enrich current research on this
devastating disease with the hope that it will help to get us a
step closer to a much needed cure.
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